What is benign prostatic enlargement (BPE)?
Trueman P, Hood SC, Nayak USL et al. Prevalence of lower urinary
tract symptoms and self-reported diagnosed 'benign prostatic
hyperplasia', and their effect on quality of life in a
community-based survey of men in the UK. BJU Int 1999; 83:
410-415.
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America
project: benign prostatic hyperplasia. Journal of Urology 2005;
173: 1256-1261.
What causes an enlarged prostate?
Konwar R, Chattopadhyay N, Bid HK Genetic polymorphism and
pathogenesis of benign prostatic hyperplasia.. BJU Int. 2008 Aug
5;102(5):536-44.
Neuhouser ML, Kristal AR, Penson DF. Steroid hormones and
hormone-related genetic and lifestyle characteristics as risk
factors for benign prostatic hyperplasia: review of epidemiologic
literature. Urology 2004; 64: 201-11
Parsons JK. Sarma AV. McVary K. Wei JT. Obesity and benign
prostatic hyperplasia: clinical connections, emerging etiological
paradigms and future directions. Journal of Urology 2009; 182(Supp
6):S27-31
Parsons JK. Modifiable risk factors for benign prostatic
hyperplasia and lower urinary tract symptoms: new approaches to old
problems. Journal of Urology. 2007; 178: 395-40
Pearson JD, Lei HH, Beaty TH et al. Familial aggregation of
bothersome benign prostatic hyperplasia symptoms. Urology 2003; 61:
781-5
Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic
susceptibility of benign prostatic hyperplasia. J Urol 1994; 152:
115-9
Sarma AV. Parsons JK. McVary K. Wei JT. Diabetes and benign
prostatic hyperplasia/lower urinary tract symptoms--what do we
know?. Journal of Urology 2009; 182 (supp 6): S32-7.
What are the symptoms?
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
Roehrborn CG. BPH progression: concept and key learning from
MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU International. 2008; 101
(supp 3): 17-21.
Am I more likely to get prostate cancer if I have an
enlarged prostate?
Young JM, Muscatello DJ, Ward JF. Are men with lower urinary
tract symptoms at increased risk of prostate cancer? A systematic
review and critique of the available evidence. BJU Int 2000;
85:1037-1048.
Schenk JM, Kristal AR, Arnold KB et al. Association of
systematic benign prostatic hyperplasia and prostate cancer:
results from the prostate cancer prevention trial. American Journal
of Epidemiology 2011: 173 (12): 1419-1428.
How might an enlarged prostate affect my
life?
Roehrborn CG. BPH progression: concept and key learning from
MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU International. 2008; 101
(supp 3): 17-21.
Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America
project: benign prostatic hyperplasia. Journal of Urology 2005;
173: 1256-1261.
Possible complications of an enlarged
prostate
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
Diagnosing an enlarged prostate
American Urological Association. 2003 (updated 2006). Guideline
on the management of Benign Prostatic Hyperplasia (BPH). Available
at http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm
[accessed January 2013]
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
Treating an enlarged prostate
Lifestyle changes
American Urological Association. 2003 (updated 2006). Guideline
on the management of Benign Prostatic Hyperplasia (BPH). Available
at http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm
[accessed January 2013]
Kaplan ST. Update on the American Urological Association
Guidelines for the Treatment of Benign Prostatic Hyperplasia.
Reviews in Urology. 2006; 8(Supp 4): S10-S17.
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on
conservative treatment of non-neurogenic male LUTS. European
Association of Urology 2010.
Medicines
Tacklind J, Fink HA, MacDonald R et al. Finasteride for benign
prostatic hyperplasisa (review). The Cochrane Collaboration
2012.
De la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines
on benign prostatic hyperplasia. European Association of Urology
2008. Available at: http://www.uroweb.org/professional-resources/guidelines/
(accessed August 2010)
Electronic medicines compendium. Summary of product
characteristics: Avodart. Available at: http://emc.medicines.org.uk/ (accessed Jannuary
2013).
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
Nickel JC, Barkin J, Koch C et al. Finasteride monotherapy
maintains stable lower urinary tract symptoms in men with benign
prostatic hyperplasia following cessation of alpha blockers. Can
Urol Assoc J. 2008; 2:16-21.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the
management of male lower urinary tract symptoms (LUTS), incl.
Benign Prostatic Obstruction (BPO). European Association of Urology
2012.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on treatment
of non-neurogenic male LUTS. European Association of Urology
2011.
Roehrborn CG. BPH progression: concept and key learning from
MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU International. 2008; 101
(supp 3): 17-21.
Surgery
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on treatment
of non-neurogenic male LUTS. European Association of Urology
2011.
Oelke M, Bachmann A, Descazeaud A et al. Guidelines on the
management of male lower urinary tract symptoms (LUTS), incl.
Benign Prostatic Obstruction (BPO). European Association of Urology
2012.
American Urological Association. 2003 (updated 2006). Guideline
on the management of Benign Prostatic Hyperplasia (BPH). Available
at http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm
[accessed August 2010]
'De la Rosette J, Alivizatos G, Madersbacher S et al. Guidelines
on benign prostatic hyperplasia. European Association of Urology
2008. Available at: http://www.uroweb.org/professional-resources/guidelines/
(accessed August 2010)
D S Engeler, C Schwab, M Neyer et al. Bipolar versus monopolar
TURP: a prospective controlled study at two urology centers.
Prostate Cancer and Prostatic Diseases 2010;13: 285-291.
Hammadeh MY, Madaan S, Hines J, et al. 5-year outcome of a
prospective randomized trial to compare transurethral
electrovaporization of the prostate and standard transurethral
resection. Urology 2003; 61: 1166-1171
Maria G, Brisinda G, Civello IM et al. Relief by botulinum toxin
of voiding dysfunction due to benign prostatic hyperplasia: results
of a randomized, placebo-controlled study. Urology 2003;
62:259-64
Martin DJ., Mulhall JP. Enlarging the scope of managing benign
prostatic hyperplasia: addressing sexual function and quality of
life. International Journal of Clinical Practice 2005;
59:579-90.
National Institute for Health and Clinical Excellence. Lower
urinary tract symptoms. The management of lower urinary tract
symptoms in men. 2010.
National Institute for Health and Clinical Excellence.
Interventional procedure overview of Transurethral
electrovaporisation of the prostate 2003. Available at http://www.nice.org.uk/nicemedia/live/11108/31070/31070.pdf
(accessed January 2013)
Tyson MD, Lerner LB. Safety of holmium laser enucleation of the
prostate in anticoagulated patients. Journal of Endourology
2009;23(8):1343-6.
Wilt TJ, Dow JN. Benign prostatic hyperplasia. Part 1 -
Diagnosis. BJU Int. 2008; 336: 146-149.